Pharma News
18 Jan 2026 to 24 Jan 2026
Jan 24, 2026
Novo Nordisk faces lawsuit for purportedly monopolizing the diabetes medication Victoza - Business Line
Novo Nordisk faces a class action lawsuit in New York for allegedly misusing patents to maintain a monopoly on its diabetes drug Victoza. The complaint, filed by Smith Drug, claims Novo engaged in a "pay-for-delay" scheme with Teva Pharmaceutical to block generic versions. The lawsuit seeks monetary damages for Victoza purchasers.
Jan 24, 2026
Delays in analyzing drug samples within the required timeframe undermine prosecutions and...
The Bombay High Court has quashed a criminal prosecution against directors of a pharmaceutical company for producing a sub-standard drug, citing the failure of government authorities to analyze drug samples within the required timeframe. The ruling emphasizes that such delays not only undermine legal actions but also pose risks to public health.
Jan 24, 2026
Abbott Healthcare Faces Investigation in India for Suspected Misuse and Redirection of Codeine
Abbott Healthcare is under investigation in India for the alleged diversion and abuse of its codeine-based cough syrup, Phensedyl. The scrutiny comes as regulators examine claims of misuse associated with the product. Abbott Laboratories, the parent company based in the U.S., is facing increased pressure amid these allegations.
Jan 24, 2026
Regeneron Shares: A Major Player in Biotechnology Faces a Pivotal Moment as Investors Anticipate Future Developments...
Regeneron Pharmaceuticals' stock is currently trading near the upper half of its 52-week range, reflecting investor sentiment on its eye drugs like EYLEA and competition risks. Analysts remain optimistic, with major firms like Goldman Sachs and J.P. Morgan issuing positive ratings. The company's focus on expanding its pipeline, particularly in oncology and immunology, could drive future growth.
Jan 24, 2026
Government suggests adding a blue vertical stripe to labels of all antimicrobial products to combat antimicrobial resistance.
The Centre has proposed new draft rules requiring all antimicrobial drugs to feature a blue vertical strip on their packaging. This initiative aims to combat antimicrobial resistance (AMR) linked to excessive over-the-counter usage.
Jan 23, 2026
Sun Pharma Receives Approval for Generic Version of Wegovy in India - Whalesbook
Sun Pharmaceutical Industries has received regulatory approval to manufacture and market a generic version of Novo Nordisk's weight-loss drug Wegovy in India. The generic semaglutide, branded as Noveltreat, will launch after the patent expires in March 2026, positioning Sun Pharma to compete in the growing weight-loss market alongside Dr. Reddy's Laboratories, which is also preparing to launch a similar product.
Jan 23, 2026
AbbVie Fails in Patent Attempt for Cancer Medication Venetoclax in India, Opening Doors for Generic Versions
India's rejection of patent protection for Venetoclax, a key cancer treatment, paves the way for local generic manufacturers to produce affordable versions. This decision is expected to enhance patient access and reduce treatment costs significantly. AbbVie is still pursuing another patent related to Venetoclax, which is under legal scrutiny. The ruling has been positively received by patient advocacy groups.
Jan 23, 2026
Sun Pharma obtains regulatory clearance to market generic Wegovy in India | Company News
Sun Pharmaceutical Industries has received regulatory approval to manufacture and sell a generic version of the weight-loss drug Wegovy, using the active ingredient semaglutide. The drug will be marketed as Noveltreat in India after the semaglutide patent expires in March 2026. Sun Pharma follows Dr Reddy's Laboratories, which also received approval for generic semaglutide.
Jan 23, 2026
Sun Pharma receives approval to market generic Wegovy in India - The HinduBusinessLine
Sun Pharmaceutical has received approval from the DCGI to manufacture and market a generic version of semaglutide injection, branded as Noveltreat, following the patent expiry in India. This move aligns with other companies like Dr Reddy’s, Cipla, and Lupin, aiming to enter the market for weight loss and diabetes treatments. Sun Pharma's Sematrinity for type 2 diabetes will launch post-patent expiry.
Jan 23, 2026
Sun Pharma receives approval to market generic Wegovy in India - WKZO
Indian drugmakers Sun Pharmaceutical Industries, Zydus Lifesciences, and Alkem Laboratories have received regulatory approval to produce generic versions of semaglutide, the active ingredient in Novo Nordisk's weight-loss drug Wegovy and diabetes drug Ozempic. This approval, ahead of the patent expiry in March 2026, is expected to intensify competition in the obesity drug market.
Jan 23, 2026
Sun Pharma authorized to market generic Wegovy, boosting competition in India's obesity medication sector.
Sun Pharmaceutical Industries has received regulatory approval to manufacture and sell semaglutide, the generic version of Wegovy, in India, marketed as Noveltreat. This approval allows entry into a $150 billion global market. Sun Pharma is the second Indian company to gain this approval, following Dr Reddy’s Laboratories, and plans to launch a generic Ozempic named Sematrinity.
Jan 23, 2026
Sun Pharma receives approval from DCGI for its generic version of semaglutide aimed at weight management, set to launch soon.
Sun Pharma has received approval from the DCGI to launch a generic version of semaglutide, branded as Noveltreat, for weight management in India after the patent expiry. The drug, a GLP-1 receptor agonist, will be available in five dose strengths following successful Phase III trials. It aims to provide a cost-effective alternative to existing high-priced products.
Jan 23, 2026
Sun Pharma receives approval to introduce a generic version of semaglutide in India; market for anti-obesity medications...
Sun Pharmaceutical Industries has launched a generic version of semaglutide, the active ingredient in Novo Nordisk's weight-loss drug Wegovy and diabetes drug Ozempic. Approved by the Drugs Controller General of India, the generic, branded as 'Noveltreat', will be available in March in five dose strengths, administered via a prefilled pen. Pricing details have not been disclosed.
Jan 23, 2026
AstraZeneca files lawsuit against Pharmacor regarding the introduction of a generic diabetes medication | Lawyerly
AstraZeneca has filed a lawsuit against Pharmacor regarding its intention to launch a generic version of the diabetes drug Forxiga on the PBS. The case centers on the validity of AstraZeneca's patent, which was previously invalidated by a UK court.
Jan 23, 2026
Initial approvals for generic semaglutide pave the way for market entry in India - Business Standard
Sun Pharmaceutical has received approval from the Drugs Controller General of India to manufacture and market a generic semaglutide injection, branded as Noveltreat, for chronic weight management. This follows the upcoming patent expiration of semaglutide, developed by Novo Nordisk. Other companies, including Zydus Lifesciences and Alkem Laboratories, have also received approvals for various semaglutide formulations. Cipla is considering entering the market post-patent expiry.
Jan 23, 2026
Eli Lilly's Cancer Medications Set to Shine Before Q4 Earnings Report - TradingView
Eli Lilly (LLY) reported $6.77 billion in oncology sales for the first nine months of 2025, a 9% increase year-over-year. The fourth-quarter sales estimate is $2.64 billion, driven by the breast cancer drug Verzenio and the newly launched Inluriyo. Despite competition from AstraZeneca, Merck, and Pfizer, Lilly's oncology unit shows consistent growth, reassuring investors ahead of earnings on February 4.
Jan 23, 2026
Pressure Mounts on Indian Generic Pharmaceuticals - Chinadaily.com.cn
Indian generic drugs are gaining global popularity for their affordability, exemplified by Cipla's reduction of anti-AIDS therapy costs from $30-$40 to under $1. However, the industry faces challenges, including limited regulatory oversight and compliance pressures, with over 60% of small firms at risk of closure. India produces 60,000 branded generics, supplying 20% of the global market.
Jan 23, 2026
Eli Lilly's Cancer Medications Set to Shine Before Q4 Earnings Report - Finviz
Eli Lilly (LLY) reported $6.77 billion in oncology sales for the first nine months of 2025, a 9% increase year-over-year. The fourth-quarter sales estimate is $2.64 billion, driven by the breast cancer drug Verzenio and the newly launched Inluriyo. Despite competition from AstraZeneca, Merck, and Pfizer, LLY's stock has risen 35% in six months, though earnings estimates have slightly declined.
Jan 23, 2026
Telangana DCA Confiscates 109 Unlabeled Oxytocin Injections in Adilabad
The Telangana Drugs Control Administration (DCA) and Adilabad Police seized 109 unlabelled oxytocin injections in a significant enforcement operation. The action highlights ongoing efforts to regulate pharmaceutical safety and prevent the distribution of unapproved medical products.
Jan 23, 2026
Sun Pharma receives DCGI authorization for weight loss medication following the expiration of Wegovy's patent.
Sun Pharmaceuticals Industries has received approval from the Drug Controller General of India to manufacture and sell a generic version of the weight-loss drug Wegovy, known as Noveltreat, containing semaglutide. The launch is expected after the patent expires in March 2026. Sun Pharma is the second Indian company to gain this approval, following Dr. Reddy’s Laboratories.
Jan 23, 2026
Sun Pharma Receives Approval from DCGI for Generic Weight-Loss Medication During Ongoing Patent Dispute with Novo Nordisk
Sun Pharma has received approval from the DCGI to manufacture and export its semaglutide formulation, amid a patent dispute with Novo Nordisk over the active ingredient used in drugs like Ozempic and Wegovy. The Delhi High Court has permitted this but restricted domestic sales in India until Novo Nordisk's patent expires in March 2026.
Jan 23, 2026
Patent denial for multinational corporation's cancer medication; generics expected to launch in the market - The Economic Times
The Indian Patent Office has denied AbbVie's patent application for the cancer drug Venetoclax, citing insufficient inventive steps and therapeutic efficacy. This ruling may pave the way for more affordable generic versions of the drug in India, following opposition from seven parties.
Jan 23, 2026
International Health Organizations Release Critical Alerts About Counterfeit and Unapproved Health Products
Global health authorities in the U.S. and Canada have issued urgent warnings about the proliferation of fraudulent and unauthorized health products. These alerts, issued in January 2026, highlight the dangers posed by misbranded items being sold online and through unauthorized channels, emphasizing the need for consumer vigilance.
Jan 23, 2026
Indian Patent Office denies AbbVie's patent application for the cancer medication Venetoclax, paving the way for generic versions to potentially enter the market.
The Indian Patent Office has rejected AbbVie’s patent application for Venetoclax, marketed as Venclexta, citing a lack of inventive step. This decision may facilitate the entry of lower-cost generics, improving access to treatment for blood cancers like CLL and AML. AbbVie still faces challenges with another related patent.
Jan 23, 2026
Bio-Thera Solutions discovers novel HER2-targeted antibody-drug conjugates | BioWorld
Bio-Thera Solutions Ltd. has developed new HER2-targeted antibody-drug conjugates that combine trastuzumab with exatecan. This innovative approach aims to enhance treatment options for cancer, inflammation, autoimmune disorders, and infections.
Jan 22, 2026
Zydus introduces a groundbreaking cancer medication at a significantly lower price - India Today
Zydus Lifesciences has launched Tishtha, a biosimilar of the cancer drug nivolumab, priced at approximately one-fourth of the original. Nivolumab, developed by Bristol Myers Squibb, is used for various cancers. Tishtha aims to enhance affordability and access for cancer patients in India, where cancer cases are rising significantly.
Jan 22, 2026
Chemotherapy not only instills fear in cancer cells but also poses significant side effects for patients.
Hanmi Pharmaceutical's new drug, Rolontis (Rollvedon in the U.S.), has gained FDA approval to prevent neutropenia during chemotherapy. Utilizing the LAPSCOVERY™ technology, Rolontis offers effective treatment with a lower dose of 3.6mg compared to competitors' 6mg. The drug has achieved significant sales, nearing 100 billion won in the U.S. and over 10 billion won in Korea.
Jan 22, 2026
Zydus Introduces Cost-Effective Cancer Medication Tishtha, Reducing Treatment Expenses in India
Jan 22, 2026
ABBV and MRK: A Competitive Landscape in Oncology and Immunology for Investors - Finviz
Merck (MRK) and AbbVie (ABBV) are key players in oncology and immunology, with AbbVie’s Humira, Skyrizi, and Rinvoq driving growth, while Merck's Keytruda remains a top revenue source. AbbVie is well-positioned for future growth despite challenges, while Merck faces potential issues with Keytruda's patent expiration. AbbVie is currently favored for its robust pipeline and revenue growth prospects.
Jan 22, 2026
Specialists Point Out Lack of Action Despite Monthly Alerts on Inferior and Counterfeit Medications
Experts criticize India's drug regulatory system, particularly the Central Drugs Standard Control Organisation (CDSCO) and state Food and Drug Administrations (FDAs), for ongoing failures in addressing substandard and spurious medicines. Despite monthly alerts regarding these issues, there has been little action taken to improve drug quality regulation.
Jan 22, 2026
Lexaria Secures Six New Patents - TheNewswire
Lexaria Bioscience Corp. (Nasdaq: LEXX) has achieved a significant milestone with 60 patents granted globally, enhancing its intellectual property portfolio. Recent patents include sublingual nicotine delivery, hypertension treatments in the EU, and epilepsy and diabetes treatments. The company urges shareholders to vote at the upcoming Annual Meeting on January 27, 2026. For more information, visit www.lexariabioscience.com.
Jan 22, 2026
An Analytical Framework for Licensing AI-Enhanced Drug Discovery Platforms | JD Supra
Artificial intelligence (AI) is revolutionizing drug discovery, enhancing processes like target identification and compound optimization. Companies are exploring licensing agreements for AI-generated compounds, with considerations around patentability, data ownership, and confidentiality. As AI platforms evolve, firms must navigate complex legal landscapes to protect intellectual property and ensure compliance with regulatory standards.
Jan 22, 2026
Rezubio Pharmaceuticals reveals novel drug conjugates aimed at fibrosis treatment - BioWorld
Rezubio Pharmaceuticals Co. Ltd. has announced the development of new drug conjugates featuring lysophosphatidic acid receptor 1 (LPAR1) antagonists, designed to treat fibrosis. These conjugates are covalently linked to a hydrophilic moiety via a linker, marking a significant advancement in fibrosis treatment options.
Jan 22, 2026
AI Diagnostics Company's Patent Assertions Fail to Meet Alice Standard - Law360 Healthcare Authority
A California federal judge dismissed Tempus AI's patent infringement lawsuit against Guardant Health, ruling that the claims in Tempus AI's patents were not eligible for patent protection under the Alice test.
Jan 22, 2026
Patent denial for multinational corporation's cancer medication, generics expected to emerge | India News - The Times of India
The Indian Patent Office has rejected AbbVie's patent application for its cancer drug Venetoclax, marketed as Venclexta, citing a lack of inventive step. This decision could allow for affordable generics in India, as the application was deemed "obvious" and not significantly enhancing therapeutic efficacy, violating Section 3(d) of the Indian Patent Act.
Jan 22, 2026
Johnson & Johnson Overcomes Patent and Pricing Challenges - The Daily Upside
Johnson & Johnson aims to be the first healthcare company to achieve $100 billion in annual revenue, surpassing $94 billion in 2025. Despite a significant drop in sales of its psoriasis drug Stelara, J&J's other products, including cancer treatments Darzalex and Carvykti, are driving growth. The company also faces ongoing legal challenges related to its talc products.
Jan 22, 2026
Zydus introduces a groundbreaking cancer medication at a significantly reduced price. - Hyderabad News
Zydus Lifesciences has launched Tishtha, a biosimilar of the cancer drug nivolumab, priced at approximately one-fourth of the original. Nivolumab, developed by Bristol Myers Squibb, is used for various cancers. Tishtha aims to enhance affordability and access for cancer patients in India, where cancer cases are rising significantly.
Jan 22, 2026
[Illustrations] Changes in the Global Blockbuster Drug Market by 2026: Keytruda Maintains Top Position
In 2026, Merck's Keytruda remains the top-selling drug, while Eli Lilly and Novo Nordisk's "diabesity" treatments gain prominence. The U.S. Inflation Reduction Act introduces Maximum Fair Prices, impacting drug pricing strategies. Keytruda's revenue is projected to exceed $30 billion, but a patent cliff looms. Eli Lilly's Mounjaro and Zepbound show strong market potential, reshaping industry dynamics.
Jan 21, 2026
The Intersection of Medical Misogyny and Marketing Addiction in Nineteenth-Century Patent Medicine...
A recent article highlights the exploitation of women in the healthcare system, tracing parallels between the nineteenth-century patent medicine industry and today's ketamine clinics. While therapeutic ketamine is marketed as a solution for conditions like postpartum depression, concerns about its safety and efficacy persist. The article emphasizes the ongoing medical misogyny and the need for genuine support rather than exploitative practices.
Jan 21, 2026
Significant obstacles persist for generic versions of Entresto - dailypharmkorea
Entresto, Novartis' heart failure drug, achieved KRW 79.4 billion in prescriptions last year, a 2.5-fold increase since 2021. Despite a Supreme Court ruling resolving patent disputes, generic versions face approval delays due to Entresto's unique co-crystal structure. As a result, no generics have been approved yet, creating a regulatory bottleneck despite the lifted patent barriers.
Jan 21, 2026
Indian Pharmaceutical Sector Q3: Stable Revenue, Profit Decline Due to US Generic Drugs and Increasing Expenses
Indian pharmaceutical companies are expected to see steady revenue growth of 8-9% in Q3, driven by domestic demand and specialty products. However, profit margins are under pressure due to price erosion in the U.S. generics market and rising operational costs. Companies like Dr. Reddy's Laboratories, Cipla, and Lupin Limited are highlighted, with Lupin anticipated to outperform peers.
Jan 21, 2026
Confirmed: Carvykti is a major success | ApexOnco - Oncology Pipeline
Johnson & Johnson's Carvykti has exceeded $1.9 billion in sales for 2025, following its April 2024 approval for second-line multiple myeloma. This marks a significant milestone for the anti-BCMA Car-T therapy, despite criticism from rival Arcellx regarding safety concerns. Meanwhile, J&J's other anti-BCMA drug, Tecvayli, saw a more modest 22% sales increase.
Jan 21, 2026
Johnson & Johnson Targets $100 Billion in Revenue, Moves Past Stelara Patent Expiration - BioSpace
Johnson & Johnson aims for $100 billion in revenue by 2026, following a successful 2025 with $94.2 billion in sales. Despite a decline in Stelara revenue, growth in treatments like Tremfaya and Spravato, along with a strong oncology portfolio, bolstered results. CEO Joaquin Duato highlighted resilience against regulatory challenges and ongoing litigation related to talc products.
Jan 21, 2026
Johnson & Johnson targets $100 billion in revenue driven by growth in cancer and immune therapies - BioPharma Dive
Johnson & Johnson reported a 9.1% sales increase in Q4, reaching $24.6 billion, driven by new medicines despite a 55% drop in Stelara sales. The company forecasts 2026 sales between $100 billion and $101 billion. J&J is focusing on oncology and immunology, with plans to become a leading oncology company. However, shares fell 1% amid concerns over patent expirations and litigation.
Jan 21, 2026
Johnson & Johnson anticipates significant growth in 2026, even with a price reduction agreement - The Edge Malaysia
Johnson & Johnson reported fourth-quarter sales exceeding expectations, driven by strong growth in cancer treatments like Darzalex and Carvykti. The company anticipates 2026 sales between $100 billion and $101 billion, despite a pricing deal with the White House. Shares fell 1.4% amid ongoing talc litigation concerns. J&J also plans to separate its orthopedics unit to focus on higher-growth medical devices.
Jan 21, 2026
Understanding Ozempic Side Effects: Insights from a Diabetes Specialist on What’s Often Overlooked | Health and Me
In a recent episode of The Diary Of A CEO, Dr. Benjamin Bikman discussed the effects of the GLP-1 drug, including its role in altering digestion to promote weight loss, leading to what he termed 'Ozempic Burps.' Experts caution that intentionally slowing digestion with such drugs can be unhealthy and should only occur under strict medical supervision.
Jan 21, 2026
GSK Invests $2.2 Billion in Innovative Allergy Treatment Amidst Competition Among Major Pharmaceutical Companies
GSK is set to acquire U.S.-based Rapt Therapeutics for $2.2 billion, focusing on the experimental therapy ozureprubart, designed to prevent severe allergic reactions with long-acting injections. This acquisition, part of GSK's strategy to enhance its immunology portfolio, underscores the competitive landscape for next-generation immune therapies. The deal is expected to close in early 2026, pending regulatory approvals.
Jan 21, 2026
Supreme Court to Consider Hikma v. Amarin: Issues of Induced Infringement and Skinny Labeling in the ...
The Supreme Court will review Hikma Pharmaceuticals USA Inc. v. Amarin Pharma Inc., focusing on the induced infringement doctrine related to generic drug marketing. The case involves Amarin's Vascepa® and Hikma's generic version, which omits a patented cardiovascular indication. The ruling may clarify the balance between generic competition and the protection of method-of-use patents under the Hatch-Waxman Act.
Jan 21, 2026
GSK acquires RAPT Therapeutics' food allergy treatment for $2.2 billion - ET Pharma
GSK has agreed to acquire RAPT Therapeutics for $2.2 billion to access its experimental food allergy drug, ozureprubart, as it prepares for patent expirations on its HIV drug, dolutegravir. The deal offers RAPT shareholders $58 per share, a 65.2% premium. GSK aims to build a portfolio of long-acting medicines, with ozureprubart targeting unmet medical needs in food allergies.
Jan 20, 2026
Supreme Court to Tackle Patent Issues Related to 'Skinny Labels'
The U.S. Supreme Court will hear Hikma Pharmaceuticals' case against Amarin Pharma regarding the patent dispute over the cardiovascular drug Vascepa®. The case questions if a generic's "skinny label" can protect it from liability for inducing patent infringement. The outcome could significantly impact generic drug competition and patent enforcement, with broader implications for the pharmaceutical industry.
Jan 20, 2026
Biosimilar manufacturers are set for a third surge as patents for major drugs approach their expiration dates.
Celltrion Holdings Co. has secured $732 million in funding to acquire shares in its biosimilar unit, Celltrion Inc. The company plans to invest half of this amount within the year to enhance its operations and pursue mergers and acquisitions.
Jan 20, 2026
Supreme Court to Hear Case of Hikma vs. Amarin | Morrison & Foerster LLP - JDSupra
The Supreme Court has granted certiorari in Hikma Pharmaceuticals v. Amarin Pharma, addressing induced patent infringement related to generic drugs. The case questions whether Hikma's marketing of a "skinny label" generic, which carves out a patented use, constitutes encouragement of infringement. The Court's decision could impact patent litigation standards across industries. Merits briefing is expected to conclude by April 2026.
Jan 20, 2026
Supreme Court to Settle Controversy Regarding Promotion of "Skinny Labeled" Generic Drugs | JD Supra
The Supreme Court has granted certiorari in the case of Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc., concerning the marketing practices of Hikma's generic version of Vascepa® (icosapent ethyl). The Federal Circuit previously ruled that Hikma's promotional statements could potentially induce patent infringement, raising concerns about the implications for generic drug marketing under the Hatch-Waxman Act.
Jan 20, 2026
McCarter & English Avoids Malpractice Lawsuit Over Drug Patent Lien - Bloomberg Law News
The New Jersey Superior Court Appellate Division ruled that McCarter & English will not face malpractice claims from Moerae Matrix, a lung disease drugmaker. The firm had placed liens on Moerae Matrix's patents after the company failed to pay over $800,000 in legal fees, winning a collection action in 2019.
Jan 20, 2026
US Supreme Court's ruling on 'skinny labels' might not deter the market, according to generics' concerns | MLex
The US Supreme Court will hear Hikma Pharmaceuticals' appeal regarding potential liability for induced infringement of Amarin Pharma patents related to "skinny labels." Generic and biosimilar manufacturers, along with the US Solicitor General, warn that a ruling against Hikma could threaten the generic drug market, although some legal experts consider the case overblown.
Jan 20, 2026
On the 20th, ISU ABXIS revealed that it has exported technology (L/O) to Russian through ISU305.
ISU ABXIS announced that its biosimilar ISU305, a treatment for PNH, has received product approval from Russian health authorities after successful phase 3 trials. ISU305 is a biosimilar of Soliris (eculizumab), originally developed by Alexion, now part of AstraZeneca. The Russian market for eculizumab is estimated at $55 million, with ISU305 targeting a 10% market share in its first year.
Jan 20, 2026
Pharmaceutical executives share their outlook on the industry's future regarding drug costs, patent expirations, and upcoming agreements.
At the JPMorgan Healthcare Conference, drugmakers discussed strategies for 2026 amid patent expirations and drug pricing reforms under President Trump's policies. Pfizer CEO Albert Bourla expressed optimism about the sector's recovery, while Merck and Bristol Myers Squibb outlined plans to offset revenue losses from patent expirations. Novo Nordisk anticipates price pressures due to generic competition for its diabetes drug Ozempic.
Jan 20, 2026
GSK Expands Its Immunology Portfolio with $2.2 Billion Acquisition of Rapt Therapeutics and Food Allergy Treatment
GSK has announced a $2.2 billion acquisition of Rapt Therapeutics to expand its immunology portfolio into food allergies. GSK will pay $58 per share for Rapt, which includes the promising monoclonal antibody ozureprubart, designed to inhibit IgE and potentially allow for dosing every 12 weeks. This acquisition aligns with GSK's strategy to enhance its respiratory and immunology expertise.
Jan 20, 2026
New Weight-Loss Medications Offer 'Significant' Outcomes: Amylin, Retatrutide, and GLP-1 Tablets
A new era in weight-loss treatments is emerging with GLP-1 drugs like Ozempic, Wegovy, and Zepbound leading the way. Experts highlight a pipeline of innovative medications, including amylin analogs and the triple-action retatrutide from Eli Lilly, which shows promising results. As options expand, patients may soon have alternatives to weekly injections, including daily pills and monthly shots.
Jan 20, 2026
Benefits and obstacles of generic medications in India - Xinhua
Indian generic drugs, led by companies like Cipla, have gained global traction for their affordability, significantly reducing treatment costs, such as anti-AIDS therapy from $30-40 to under $1. However, challenges persist, including regulatory limitations and quality oversight, with the U.S. and EU tightening standards. India's pharmaceutical industry, producing 60,000 branded generics, faces potential instability due to compliance pressures.
Jan 20, 2026
CJEU to determine whether approval for human medication excludes SPC for veterinary applications
Boehringer Ingelheim's application for a supplementary protection certificate (SPC) for its veterinary drug Aservo EquiHaler, containing ciclesonide, was rejected by the German Patent Office due to prior approval of Covis Pharma's Alvesco for human use. The German Federal Patent Court has referred the case to the CJEU for clarification on SPC eligibility regarding active substances.
Jan 19, 2026
J Sai Deepak discusses | Patent protections and health care: What choices does India have?
In a recent article, the author discusses the balance between enforcing intellectual property rights (IPRs) and public health in Bharat. They argue against "evergreening patents" in the pharmaceutical sector, emphasizing that protecting public health should not be seen as protectionism. The article calls for Bharat to utilize its TRIPS rights to address abusive practices by pharmaceutical innovators from the Global North.
Jan 19, 2026
iX Biopharma's expansion driven by drug delivery patent | The Straits Times
iX Biopharma is leveraging its patented WaferiX sublingual drug delivery technology to expand its product portfolio and partnerships in the U.S. The company’s lead asset, Wafermine, a sublingual ketamine for pain, is set for Phase 3 trials. A joint venture with Orion Specialty Labs will facilitate entry into the U.S. compounding pharmacy market, enhancing growth opportunities.
Jan 19, 2026
Delhi High Court affirms the denial of patent for cancer detection technique using nematodes | India News
The Delhi High Court has upheld the rejection of Hirotsu Bio Science Inc.'s patent application for a nematode-based cancer detection method, ruling it a non-patentable diagnostic process under Section 3(i) of the Patents Act, 1970. The court emphasized that the method, despite being labeled as "screening," constitutes a diagnostic process and cannot be patented.
Jan 19, 2026
US Supreme Court hears case regarding 'skinny' generic label for Vascepa - pharmaphorum
The US Supreme Court will hear a patent dispute between Amarin and Hikma regarding the legality of 'skinny labels' for generic drugs. Amarin's Vascepa (icosapent ethyl) is at the center of the case, which could impact how generic manufacturers navigate patent protections. Hikma's generic, launched in 2020, has faced legal challenges from Amarin over its marketing practices.
Jan 19, 2026
Supreme Court Set to Examine CAFC's Decision on Induced Infringement in Hikma vs. Amarin Case
The U.S. Supreme Court has agreed to hear Hikma Pharmaceuticals' appeal regarding Amarin Pharma's patent infringement claims related to Hikma's generic omega-3 product. The case questions whether Hikma's public statements about its generic product induce infringement of Amarin's patented uses. The U.S. Solicitor General argues that such statements should not lead to liability, emphasizing the importance of the Hatch-Waxman Act.
Jan 19, 2026
Solicitor General Makes Compelling Case; Supreme Court Approves Hikma's Certiorari Request
The Supreme Court has granted Hikma Pharmaceuticals' certiorari petition in a case concerning induced infringement related to off-label prescribing of generic drugs. The Court will consider whether generic labels that exclude patented uses can still lead to infringement claims. This decision could impact drug pricing and the availability of generics, reflecting ongoing concerns about high medication costs.
Jan 19, 2026
Three companies get positive endorsement from the SEC for their semaglutide formulations.
Novo Nordisk's patent for semaglutide, its leading anti-obesity and diabetes drug, will expire in March 2026. The Indian Subject Expert Committee has approved Torrent Pharmaceuticals, MSN Laboratories, and Natco Pharma to manufacture generic versions. This could create a revenue opportunity exceeding Rs. 5,000 crore for generics in India, with prices potentially dropping 30%-75% post-launch.
Jan 19, 2026
Employers are reevaluating healthcare offerings as weight-loss medications transform workplace benefits.
UK employers are reassessing healthcare strategies as demand for weight-management drugs like Ozempic rises. A report by Howden Employee Benefits reveals over a quarter of workers have used such drugs, prompting 44% of employers to review their healthcare plans. While these drugs can reduce long-term health risks, rising costs pose challenges, with medical inflation expected to reach 7% by 2026.
Jan 19, 2026
41% of employees seek inclusion of weight-management medications in their health insurance plans - Cover Magazine
A report by Howden reveals that 26% of UK employees have used blockbuster GLP-1 weight-management drugs like Ozempic, prompting 44% of employers to revise healthcare plans. However, the rising costs associated with these drugs are creating challenges for businesses, with 50% now viewing weight-management drug coverage as a financial burden.
Jan 19, 2026
JP Morgan 2026 Recap: Pharmaceutical Executives Discuss the Conference and Industry Outlook...
At the 44th annual JP Morgan Healthcare Conference, major pharma leaders, including Merck's Rob Davis and Eli Lilly's David A. Ricks, emphasized pipeline expansion and new blockbuster drugs by 2030. Notable M&A deals included Boston Scientific's $14.5 billion acquisition of Penumbra and AbbVie's $5.6 billion licensing agreement for RemeGen's RC148. The conference highlighted the industry's focus on innovation and collaboration.
Jan 19, 2026
Pfizer (PFE) Confronts Patent Expiration Challenges Amidst $146 Billion Market Valuation | Intellectia.AI
Wall Street analysts predict a rise in Pfizer Inc. (PFE) stock, with an average 1-year price target of $28.56. UBS initiated coverage with a Neutral rating and a $25 target, citing revenue uncertainty. BofA and Morgan Stanley also downgraded their targets to $27 and $28, respectively, amid concerns over COVID-19 product erosion and exclusivity losses.
Jan 19, 2026
Pfizer's Stock Plummets 55%: Is Now the Time to Invest? - The Globe and Mail
Pfizer's stock has dropped 55% from its pandemic highs due to a key drug failure and looming patent expirations, leading to concerns about its future. Despite this, Pfizer remains a significant player in the pharmaceutical industry, with a $145 billion market cap. The company is actively seeking new opportunities, including acquiring a firm with a promising GLP-1 pipeline.
Jan 19, 2026
K-Bio Takes on FDA's Latest Medication Approval - IT조선
Korean pharmaceutical companies HK inno.N and HLB are intensifying efforts to secure FDA approvals for their drugs this year. HK inno.N has submitted a New Drug Application for its GERD drug K-CAB (tegoprazan), while HLB plans to resubmit for its liver cancer therapy. Both companies aim to enhance their global market presence, reflecting Korea's growing role in the pharmaceutical industry.
Jan 18, 2026
Pharmaceutical companies increase prices in 2026. What will be your additional expenses? - USA Today
In January 2026, pharmaceutical companies, including Pfizer, Novo Nordisk, and Eli Lilly, raised prices on over 850 drugs by a median of 4%. Notable increases include a 15% hike for Pfizer's COVID-19 vaccine Comirnaty and 3% for diabetes drugs Ozempic and Mounjaro. These price hikes occur despite federal efforts to limit costs through the Inflation Reduction Act and Trump's health plan.
Jan 18, 2026
Competition Intensifies in Weight-Loss Medication Market as Generics Approach Novo and Lilly
Novo Nordisk and Eli Lilly's weight-loss drug market is under threat from the launch of oral pills and impending patent expirations, which may lead to generics entering the market. This increased competition is expected to pressure prices, especially in emerging markets, attracting interest from Indian pharmaceutical firms looking to expand exports.
Jan 18, 2026
Reasons a major cancer medication may soon become significantly more affordable in India
The Delhi High Court has ruled in favor of Zydus Lifesciences, allowing the Indian company to produce a cheaper biosimilar version of the cancer drug Nivolumab, marketed as Opdyta in India. The court emphasized public interest, as the patent held by Bristol Myers-Squibb (BMS) expires in May. Zydus claims its version could be 70% cheaper, improving access for patients.
